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ABSTRACT: Improved in vitro models are needed to better understand cancer progression and bridge 
the gap between in vitro proof-of-concept studies, in vivo validation, and clinical application. Multicellular 
tumor spheroids (MCTS) are a popular method for three-dimensional (3D) cell culture, since they capture 
some aspects of the dimensionality, cell-cell contact, and cell-matrix interactions seen in vivo. Many 
approaches exist to create MCTS from cell lines, and they have been used to study tumor cell invasion, 
growth, and how cells respond to drugs in physiologically-relevant 3D microenvironments. However, there 
are several discrepancies in the observations made of cell behaviors when comparing between MCTS 
formation methods. To resolve these inconsistencies, we created and compared the behavior of breast, 
prostate, and ovarian cancer cells across three MCTS formation methods: in polyNIPAAM gels, in 
microwells, or in suspension culture. These methods formed MCTS via proliferation from single cells or 
passive aggregation, and therefore showed differential reliance on genes important for cell-cell or cell-
matrix interactions. We also found that the MCTS formation method dictated drug sensitivity, where 
MCTS formed over longer periods of time via clonal growth were more resistant to treatment. Towards 
clinical application, we compared an ovarian cancer cell line MCTS formed in polyNIPAAM with cells from 
patient-derived malignant ascites. The method that relied on clonal growth (PolyNIPAAM gel) was more 
time and cost intensive, but yielded MCTS that were uniformly spherical, and exhibited the most 
reproducible drug responses. Conversely, MCTS methods that relied on aggregation were faster, but 
yielded MCTS with grape-like, lobular structures. These three MCTS formation methods differed in culture 
time requirements and complexity, and had distinct drug response profiles, suggesting the choice of 
MCTS formation method should be carefully chosen based on the application required. 
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INTRODUCTION  
Two-dimensional (2D) cell culture monolayers are traditionally used to study cancer biology, gain 
insight into mechanisms of cancer progression, and screen for novel anti-cancer treatments. However, 
traditional 2D cell culture platforms used in drug screening do not accurately model cancer tumors1-3, as 
they lack cell heterogeneity, differentiated phenotypes, extracellular matrix (ECM) architecture, and drug 
resistance seen in vivo4-7. In vitro model systems that can better mimic the in vivo microenvironment could 
improve therapeutics discovery by reducing false positives that later fail in pre-clinical or clinical trials. 
Three-dimensional (3D) cell culture models can recapitulate some of the physiological behavior of in vivo 
tumors5,8, including non-uniform distribution of oxygen and nutrients1 and multicellular drug resistance9. 
Moreover, gene expression profiles of 3D cell culture models are often closer to gene expression profiles 
of tumors than 2D models4,10-11. Therefore, 3D models can better reflect some of the complexity of tumors 
that impact biological responses, such as drug resistance, angiogenesis, cell migration, cell invasion, and 
metastasis5,12. 
The most common approach for 3D cell culture models is the multicellular tumor spheroids 
(MCTS) model13-14, which can be applied to established cancer cell lines or samples isolated from 
patients15. MCTS are characterized by a 3D structure with strong cell-cell and cell-ECM interactions, 
which make them more similar to in vivo tumors over 2D cell monolayers2,7. Unlike 2D models, MCTS 
models can also recapitulate the oxygen and nutrient gradients seen in vivo16-18. Because of these 
features, MCTS have been used to study tumor biology, and for high-throughput drug screening9,12,15,19. 
MCTS are used in development and testing several therapeutic approaches like chemotherapy, 
radiotherapy, and immunotherapy19-21. Additionally, many researchers have found increased resistance in 
MCTS compared to cells on tissue culture polystyrene (TCPS)22-27. Despite these attributes, several 
factors limit the use of MCTS in drug discovery and development, including the need to 1) produce high 
quantities of uniform MCTS28-29, 2) predictably control MCTS size for consistent results16, and 3) technical 
adaptation of existing screening assays to 3D MCTS models28-29. Addressing these limitations could make 
3D high-throughput drug screening methods more suitable to commercial development. 
Current MCTS formation techniques include stationary or rotating culture incubation systems. 
Stationary formation systems include the liquid-overlay technique, the hanging drop method, and the 
suspension method in non-adherent plates 1,30. The advantages of these systems are low cost, easy 
operation, and production of reproducible MCTS31. However, they yield very few MCTS, which limits their 
adaptation to large scale studies. Rotating formation systems include the spinner flask method, the 
gyratory rotation system, and the roller tube system1,30. The advantages of these techniques include 
massive production and control of culture conditions31, while the biggest limitations are the infrastructure, 
and high quantities of medium and drugs required30. Although these methods each have their 
advantages, the existence of multiple MCTS formation methods introduces variability in MCTS size, 
shape, and formation ability14,32-33. To the best of our knowledge, this is the first work that compares 
MCTS formation methods in terms of the implications in gene expression and drug response, which may 
improve future studies across many applications, such as high-throughput drug screening. 
In this study, we explored how three MCTS formation methods changed gene expression and 
drug response in breast, prostate, and ovarian cancer cells. These methods required either aggregation 
followed by compaction or clonal proliferation, probably leading to different subpopulations of cells in the 
resulting MCTS. Although each method produced similar size MCTS, different methods lead to different 
expression profiles of cell-cell and cell-matrix interaction genes. Moreover, the MCTS formation methods 
used dictated drug sensitivity, suggesting significant implications to improve future drug screening 
studies.  
 
MATERIALS AND METHODS 
Cell culture. All cell lines were cultured at 37C and with 5% CO2 unless otherwise noted. Cell 
culture supplies were purchased from Thermo Fisher Scientific (Waltham, MA) with the exception of 
bovine insulin (Sigma-Aldrich, St. Louis, MO). The cell lines AU565, BT549, BT474, HCC 1395, HCC 
1419, HCC 1428, HCC 1806, HCC 1954, HCC 202, HCC 38, LNCaPcol, HCC 70, PC-3, SKOV-3, ZR-75-
1 were cultured in Roswell Park Memorial Institute (RPMI) medium supplemented with 10% fetal bovine 
serum (FBS) and 1% penicillin/streptomycin (Pen/Strep). OVCAR-3 cells were cultured in RPMI with 20% 
FBS, 1% Pen/Strep, and 0.01 mg/ml bovine insulin. Hs578T, MCF7, MDA-MB-468, MDA-MB-231, MDA-
MB-231 BoM (bone tropic), MDA-MB-231 BrM2a (brain tropic), MDA-MB- 231 LM2 (lung tropic), SkBr3 
were cultured in Dulbecco’s Modified Eagle Medium (DMEM) with 10% FBS, 1% Pen/Strep. MDA-MB-
175 was cultured in Leibovitz's L-15 medium with 10% FBS and 1% Pen/Strep without supplemental CO2, 
and MDA-MB-134 and MDA-MB-361 were cultured in Leibovitz's L-15 medium with 20% FBS and 1% 
Pen/Strep without supplemental CO2. The media described for their respective cell lines will be referred to 
as “routine culture medium” and any modifications will be noted where applicable. Highly metastatic MDA-
MB-231 variants isolated from in vivo selection (BoM, BrM2a, and LM2) were kindly provided by Joan 
Massagué34-36, MDA-MB-231 by Sallie Smith Schneider, BT549, MCF7, and SkBr3 by Shannon Hughes, 
PC3 by Evan Keller, and LnCaPcol derived through serial passage on collagen type I from LNCaP by 
Michael Long37. SKOV-3 and OVCAR-3 were purchased from ATCC, and all others were kindly provided 
by Mario Niepel. 
PolyNIPAAM MCTS. Single cells were suspended at 100 cells/μL in polyNIPAAM (Cosmo Bio 
USA, Carlsbad, CA) on ice and gelled as 150 μL volumes at 37°C for 5 minutes. Routine culture medium 
or routine culture medium + 100 ng/mL epidermal growth factor (EGF, R&D Systems, Minneapolis, MN) 
was added and medium was changed every 2-3 days until MCTS were collected at Day 14. MCTS were 
recovered from polyNIPAAM by replacing the cell culture medium with serum free medium at 4C and 
placing them on ice for 5 minutes. The dissolved gel was diluted in additional serum free medium and put 
in a conical tube to concentrate the MCTS via gravity sedimentation on ice for 30 minutes. The MCTS 
pellet was lysed for RT-PCR, or used for encapsulation in 3D hydrogels. MCTS were handled using cut 
pipette tips to minimize shear stress. 
Microwells MCTS. Square pyramidal micro-wells (400 μm side-wall dimension) were fabricated 
as described previously38-39 or purchased (AggreWell, Stem Cell Technologies, Canada). For fabrication, 
master molds containing square-pyramidal pits were generated by anisotropic etching of 100 crystalline 
silicon in potassium hydroxide (KOH). Microwells surfaces for tissue culture were then generated from 
poly(dimethylsiloxane) (PDMS) using a two-stage replica molding process off the master mold as 
described previously38-39. Microwells were arranged in a square array with no space between adjacent 
wells and placed in 6 or 12-well plates. To prepare microwells for cell seeding, microwells surfaces were 
UV sterilized and pretreated with 5% Pluronic F-127 (Sigma Aldrich) for 30 minutes at room temperature 
and then washed twice with sterile water. Cells were distributed over microwells surfaces at 
concentrations of 1.03 x 105 cells/cm2 or 1.00 x 104 cells/cm2. After 24 hours, MCTS were collected by 
shaking the plate gently to dislodge most of them, and gently aspirating medium and MCTS. MCTS 
solution was spun down at 400 rpm for 5 minutes. Medium was removed, and the MCTS pellet was lysed 
for RT-PCR, or encapsulated in 3D hydrogels. MCTS were handled using cut pipette tips to minimize 
shear stress. 
Suspension MCTS. Single cells were seeded at 1.05 x 104 cells/cm2, 1.05 x 103 cells/ cm2, or 
1.05 x 102 cells/cm2 in a 6-well flat ultra-low attachment plate (Corning, Tewksbury, MA). After 3 days, 
MCTS were collected by aspiration of medium and MCTS. MCTS solution was spun down at 400 rpm for 
5 minutes. Medium was removed, and the MCTS pellet was lysed for RT-PCR or encapsulated in 3D 
hydrogels. MCTS were handled using cut pipette tips to minimize shear stress.  
Characterization of gene expression by RT-PCR. The expression of cell-cell adhesion 
molecules and ECM mRNA transcripts was measured by quantitative RT-PCR. Total RNA was isolated 
using the GenElute mammalian total RNA kit (Sigma-Aldrich) and 0.5 g total RNA was reverse 
transcribed using the RevertAid reverse transcription system (Thermo). 10 ng cDNA was then amplified 
using 10 pmol integrin-specific primers (Table S1) and the Maxima SYBR green master mix (Thermo) on 
a Rotor-Gene Q thermocycler (Qiagen, Valencia, CA) as follows: 50°C for 2 minutes, 95°C for 10 minutes 
followed by 45 cycles at 95°C for 10 seconds, 58°C for 30 seconds, and 72°C for 30 seconds. Both -
actin and ribosomal protein S13 were included as reference genes to permit gene expression analysis 
using the 2-Ct method40.  
PEG-maleimide (PEG-MAL) hydrogels. 3D hydrogels were prepared with a 20 kDa 4-arm PEG-
maleimide (PEG-MAL, Jenkem Technology, Plano, TX) at 10 wt% solution with 2 mM of cell adhesion 
peptide RGD (see supplemental information) and cross-linked at a 1:1 ratio with 1 kDa linear PEG-dithiol 
(Sigma Aldrich) in sterile 2 mM triethanolamine (pH 7.4). Volumes of the hydrogels were limited to 10 μL 
to avoid oxygen and nutrient diffusion limitations. Gelation proceeded for 5 minutes at 37°C to ensure 
complete polymerization before the addition of culture medium. MCTS were transferred to 3D PEG-MAL 
hydrogels; using similar seeding densities were similar for the three MCTS formation methods. 
PolyNIPAAM MCTS were encapsulated at a ratio of one 150 μL polyNIPAAM gel to nine 10 μL PEG-MAL 
hydrogels, microwells MCTS at a ratio of 4 cm2, 1 mL to nine 10 μL PEG-MAL hydrogels, and suspension 
MCTS at a ratio of 9 cm2, 3 mL to nine 10 μL PEG-MAL hydrogels. MCTS created via either polyNIPAAM, 
microwells or suspension were transferred with cut pipette tips to minimize shear stress.  
Primary ovarian cancer ascites culture. Ascites samples were received from patients 
undergoing paracentesis at UMass Medical School (Worcester, MA), were transported to UMass Amherst 
(Amherst, MA) on the day of collection, and used immediately upon receipt. Samples were de-identified 
and were IRB exempt. Pathology reports are provided in Table S2. Either single cells or ovarian 
carcinoma ascites spheroids (OCAS) were recovered from patient samples. For single cells, the ascites 
fluid was centrifuged at 1,000 rpm for 10 minutes at 4C, and the supernatant was removed. Red blood 
cells were removed by resuspending the cell pellet in cold red blood cell lysis buffer (0.83% ammonium 
chloride, 0.1% potassium bicarbonate, and 0.0037% EDTA)41. The tube was rotated at room temperature 
for 10 minutes, cells spun down at 1,000 rpm for 10 minutes at 4C, and washed with PBS once prior to 
seeding on TCPS or in polyNIPAAM. For collection of OCAS directly from the patient sample, ascites fluid 
was filtered through a 40 μm mesh cell strainer. The retained OCAS were collected by using a cut pipette 
tip on the inverted cell strainer and encapsulated directly into polyNIPAAM or 3D PEG-MAL hydrogels. 
Supernatant from ascites pellets was stored at -80C and filtered through 0.45 μm syringe filter prior to 
use as a culture medium without any additional supplements for single cell and OCAS polyNIPAAM 
culture. 
Proliferation and drug screening. AU565, BT549, SKOV-3, and primary ovarian single cancer 
cells were seeded in RPMI with 5% FBS at 6,250 cell/cm2. MCTS from the same cell lines formed in 
polyNIPAAM, microwells, and suspension were recovered and encapsulated in 3D PEG-MAL hydrogels. 
OCAS from primary ovarian cancer samples were collected and also encapsulated in 3D PEG-MAL 
hydrogels. Drugs were added after 24 hours, and cells were incubated with drugs for 48 hours. Cisplatin 
(Tocris Bioscience, United Kingdom), paclitaxel (MP Biomedicals, Santa Ana, CA), sorafenib (LC 
Laboratories, Woburn, MA), or mafosfamide (Niomech, Germany) were added in ten-fold serial dilutions 
at concentrations of 10-5-102 μM, and dimethyl sulfoxide (DMSO, Sigma-Aldrich) was used as a vehicle 
control. Viability was assayed after 48 hours of incubation using the CellTiter Glo luminescent viability 
assay (Promega, Madison, WI). Luminescence values were read in a BioTek Synergy H1 plate reader 
(Winooski, VT), and GR5042 was calculated using GraphPad Prism v6.0h (La Jolla, CA) for each cell line 
and drug. GR50 and proliferation results for the three MCTS formation methods are presented and 
discussed as relative to TCPS (fold change from the TCPS results). 
MCTS staining. MCTS in microwells plates at days 0 and 1, and from polyNIPAAM, microwells, 
and suspension encapsulated in 3D PEG-MAL hydrogels for 24 hours or 3 days, were assessed for 
viability with live/dead staining (L3224, Thermo) according to the manufacturer’s instructions, and for 
proliferation via Ki67 immunofluorescence. For the Ki67 staining, samples were rinsed three times with 
PBS, fixed with 4% formaldehyde, permeabilized with Tris-buffered saline (TBS) containing 0.5% Triton 
X-100 (Promega), and blocked with AbDil (2 wt % bovine serum albumin (BSA) in TBS with 0.1% Triton 
X-100, TBS-T). Samples were incubated for 2 hours at room temperature with the primary antibody 
(ab16667, 1:200-Abcam, UK), washed, and incubated with goat anti-Rabbit IgG (H+L) secondary 
antibody for 2 hours (Alexa Fluor 647, 1:500, Promega). Cell nuclei were labeled with DAPI at 1:10000 
(Thermo) for 5 minutes. Brightfield imaging was performed on a Zeiss Axio Observer Z1 (Carl Zeiss AG, 
Oberkochen, Germany), and fluorescence imaging on a Zeiss Spinning Disc Cell Observer SD (Zeiss).  
Statistical analysis and correlations. Statistical analysis was performed with GraphPad Prism 
v6.0h. Data shown are the averages of the means from three separate biological replicates, and the error 
bars represent standard error (95% confidence level). Patient samples had only one biological replicate 
each. Statistical significance was evaluated by two-way analysis of variance (ANOVA), followed by 
Tukey’s post-test for pairwise comparisons. Spearman rank correlation is reported as ρ with significance 
(p) determined by a two-tailed t-test. For both tests, p < 0.05 was considered statistically significant. p < 
0.05 is marked with *, ≤ 0.01 with **, ≤ 0.001 with ***, and ≤ 0.0001 with ****, p ≥ 0.05 was considered not 
significant (‘ns’). 
Image processing. Image J (NIH, Bethesda, MD) was used for diameter and circularity 
measurements of MCTS and cells, as well as compiling individual staining images. 
 
Information for “RGD synthesis” and “Gene Expression Clustering and PCA” can be found in 
Supplemental Materials and Methods.  
 
RESULTS 
 PolyNIPAAM, microwells, and suspension methods generated diverse MCTS across cell 
lines. We screened the MCTS formation abilities of 23 breast, 2 ovarian, and 2 prostate cancer cell lines 
across three different MCTS methods: polyNIPAAM gels, microwells, and suspension in non-adherent 
plates (Figures 1b, S1). For all the methods, single cells were seeded, and after 14 days (polyNIPAAM), 3 
days (suspension), or 1 day (microwells), and MCTS reached approximately 100 m. Many cell lines 
formed uniformly-sized MCTS that had at least a 2-fold increase in mean diameter, with many reaching 
approximately 100 m in diameter in 14 days (i.e., AU565, BT549, LNCaPcol, PC-3, SKOV-3, OVCAR-3, 
HCC 1419, HCC 1428, MCF7, MDA-MB-231, SkBr3, ZR-75-1, BT474). Some cell lines (i.e., HCC 1954, 
Hs578T) were incapable of growing into MCTS, and most of these cells died within the 14-day period 
(data not shown). Other cell lines formed few MCTS (i.e., HCC 1806, MDA-MB-468, MDA-MB-231 LM2, 
HCC 70), suggesting that only a small percentage of cells were capable of forming MCTS via this method. 
We observed many different morphologies across these MCTS, and they were reminiscent of 
work reported from the Bissell group that described four classes of spheroids that formed in 3D laminin-
rich ECM (3D lrECM): round, mass, grape-like, and stellate43. In polyNIPAAM, BT474 and MCF7 formed 
very compact MCTS, while SkBr3 and MDA-MB-468 formed grape-like MCTS. As for the cell lines that 
were stellate in 3D lrECM, BT549 formed compact MCTS, MDA-MB-231 formed large, loose MCTS, while 
Hs578T did not form MCTS in polyNIPAAM. Invasion or cell spreading reminiscent of the stellate 
morphology were never observed because there were no cell-matrix adhesion sites in the polyNIPAAM 
gel, and it was not cell-degradable. We did not examine any cell lines that were categorized by Bissell as 
round. 
The polyNIPAAM method allowed growth of MCTS in more than half of the cell lines tested, 
independent of breast cancer clinical subtype (data not shown). Interestingly, a negative correlation was 
found between doubling times44 and MCTS size (Figure S2a), indicating that faster growing cells produce 
bigger MCTS in polyNIPAAM. In addition, we found that most cell lines formed bigger MCTS when grown 
with supplemental EGF, although some did not change (i.e., HCC 1428, HCC 1806, BrM2a, BoM, MDA-
MB-134, MDA-MB-361, HC 1954, and Hs578T) and a few decreased in size, such as AU565, MDA-MB-
231, and MDA-MB-468, which already make large MCTS (Figure S3). The data showed that EGF caused 
only a small size increase for cell lines that formed small MCTS, while it caused larger size increases in 
the majority of the cell lines that made larger MCTS even without EGF. 
All cell lines that formed MCTS in the polyNIPAAM method were collected after 14 days of 
culture, and encapsulated into 3D PEG-MAL hydrogels. This was done to demonstrate that the MCTS 
were easily handled, and remained intact when transferred to another system. Viability was assessed 
after 3 days, and the majority of the MCTS were viable (Figure S4). There was no evidence of a necrotic 
core, but likely this was because the MCTS diameters were relatively small.   
 We next selected a subset of the cell lines that had at least a 2-fold increase in diameter in the 
polyNIPAAM method (red text in Figure 1b) to compare MCTS formation in microwells (Figure 1c) and 
suspension (Figure 1d) methods. In these aggregation methods, MCTS size increased with seeding cell 
density (Figure S5), and densities of 1.00 x 104 cells/cm2 (microwells) and 1.05 x 104 cells/cm2 
(suspension) were used to achieve MCTS sizes between 80-150 µm (Figure S6). In the microwells, the 
cells slowly coalesced into MCTS for the first ~10 hours, then the MCTS further compacted over the first 
day of culture (Figure S7 and Video S1).  MCTS from microwells were both viable and proliferative 
(Figure S8). Among the six cells lines used for the microwells and suspension methods, there was no 
correlation between MCTS size and growth rate, likely because these methods are dependent upon cell 
aggregation rather than growth (Figure S2b and c). Since MCTS in microwells compacted over time, 
circularity was found to increase, which eventually yielded more uniform MCTS. In contrast, circularity 
was preserved in polyNIPAAM throughout the growth process, and decreased in suspension (Figure S9). 
It is likely that MCTS in suspension became less compact over time because there were no solid surfaces 
that cells could contact. By contrast, cells in polyNIPAAM are confined in the gel, and cells in the 
microwells are in contact with the microwell surfaces. Together, these results demonstrated that MCTS 
can be formed with three different methods. Furthermore, the differences in culture times suggest that in 
the polyNIPAAM method single cells grew into MCTS (Figure 1 and S2a), whereas in the microwells and 
suspension methods, MCTS formed as a result of aggregation, independent of proliferation (Figure S2b-
c).  
 Fibronectin and claudin 4 expression depend on MCTS formation method. Gene 
expression was quantified in breast, prostate, and ovarian cancer cell lines in the three MCTS formation 
methods and compared to basal gene levels in 2D TCPS culture. To select the relevant genes for this 
study, RNA-Seq data was analyzed from breast cancer cell lines (MDA-MB-231 and SkBr3) that were 
grown on TCPS, in polyNIPAAM for 14 days, or grown in polyNIPAAM and then dissociated and plated 
back onto TCPS (Figure S10a; GSE93562). Using Gene Set Enrichment Analysis (GSEA), we observed 
that cell surface receptor-linked signal transduction genes, including several integrins, were enriched on 
TCPS when compared to MCTS formed in polyNIPAAM for 14 days, while cell-cell adhesion genes, such 
as claudin 4, were enriched in cells grown into MCTS in polyNIPAAM over 14 days compared to TCPS 
(Figure S10b-c). From this dataset, we selected a subset of cell adhesion genes including integrin 
subunits (α2, β1 and β4), cell-cell junction proteins (cadherins 3 and 5 and claudin 4), and the ECM 
protein, fibronectin, to examine in each MCTS formation method.  
We found that either claudin 4 or fibronectin were upregulated in all MCTS methods compared to 
TCPS (Figure 2a) with the few exceptions of OVCAR3 in polyNIPAAM, and BT549 and PC-3 in 
microwells. Gene expression patterns varied with the time required for MCTS formation across the three 
methods. Fibronectin was downregulated for all the cell lines in microwells, while claudin 4 was 
upregulated in polyNIPAAM method for all the cells lines, except for AU565 and OVCAR-3. These gene 
expression changes were dependent on the cell line as well as the MCTS formation method. Variations in 
gene expression with MCTS formation method was confirmed by dendrogram clustering for all 
combinations of examined cell lines and methods, which revealed that TCPS and polyNIPAAM primarily 
clustered together, and the shorter methods of microwells and suspension also clustered together (Figure 
2b). This was further confirmed by principal component analysis (PCA), which revealed that samples did 
not cluster by cell line or cancer type (data not shown), but rather that PC1 separated samples by 
method, with those that had the shortest and longest times of culture being the most distinct from one 
another (Figure 2c). Although all of these systems formed MCTS of similar size, the expression of cell 
contact genes varied across methods, which may have affected the compactness of MCTS. We thus 
hypothesized that MCTS that upregulated cell-cell contact genes and took longer times to form MCTS 
may be more resistant to first line therapies than 2D TCPS due to their compact morphology. 
MCTS growth method dictated drug response. To test drug resistance, we selected two breast 
cancer cell lines, one triple negative (BT549) and one HER2-enriched (AU565) for drug screening 
experiments. These subtypes have poor prognosis and they are clinically treated with chemotherapeutic 
drugs45. Breast cancer MCTS were created with the three methods, encapsulated in 3D PEG-MAL 
hydrogels, and treated with either the chemoterapeutic drugs cisplatin or paclitaxel, or the targeted drug 
sorafenib, which is a Raf kinase inhibitor46 (Figure 3a). Transferring the MCTS to the 3D PEG-MAL 
hydrogels allowed us to test cell response to the drugs as a function of MCTS formation method, 
independent of the effects of the MCTS formation platform. The maximum MCTS diameter for these two 
cell lines was kept at 150 µm (Figure S8). In all cases, the MCTS were intact and viable 24 hours after 
encapsulation in 3D PEG-MAL (Figure S11).  
MCTS proliferation was measured relative to TCPS as a baseline for cell growth across 
platforms. AU565 and BT549 cells proliferated less in all the three methods used to form MCTS 
compared to TCPS (Figure 3b). Next, drug response was determined by calculating the GR50 for MCTS 
formed by all three methods, as well as for each cell line grown on TCPS. Drug responses were reported 
as fold changes between GR50 values of each drug in individual 3D MCTS models and TCPS; a fold 
change of >1 means that the 3D MCTS model displayed greater drug resistance than TCPS. We found 
that the MCTS formation method dictated drug sensitivity. For example, AU565 cells were less sensitive 
to cisplatin in MCTS formed in polyNIPAAM compared to suspension and microwells (Figure 3b). 
However, the effect of formation method on drug response also varied between cell lines. For example, 
BT549 were more sensitive to cisplatin when they were formed in the polyNIPAAM method, and less 
sensitive when they were formed in the suspension method, while the opposite was true for AU565. We 
also found that drug response varied across drugs: AU565 MCTS cultured in microwells were significantly 
more sensitive to paclitaxel, while they were less sensitive to cisplatin and sorafenib. Interestingly, MCTS 
formed in all methods were slightly more sensitive to sorafenib than on TCPS, with the exception of 
AU565 MCTS formed in suspension. This may be because sorafenib works as a targeted agent rather 
than interfering with cell division. Overall, the microwells method sensitized MCTS to drugs, with the 
exception of the BT549 response to paclitaxel. However, MCTS created with the polyNIPAAM and 
suspension methods were more resistant to drug treatments, although the response was slightly more 
heterogeneous across conditions. We then hypothesized that MCTS formed in polyNIPAAM could show 
similar response to drugs as seen in in in vivo tumors. To test this hypothesis, we compared drug 
responses of SKOV-3 MCTS and patient-derived ovarian carcinoma ascites. 
SKOV-3 MCTS modeled primary ovarian cancer drug response. With the goal of discovering 
whether MCTS were able to recapitulate features of primary patient samples, we compared the drug 
responses of SKOV-3 MCTS with that of cells gathered from ascites of ovarian cancer patients. We 
seeded single cells and OCAS collected from patients in polyNIPAAM to determine if single cells could 
form MCTS and if OCAS seeding would increase in MCTS size. There was variation in growth for single 
cells between patients (P1, P2, and P3) and culture medium (Figure 4a). However, OCAS seeded in 
polyNIPAAM did not appreciably increase in size compared to single cells (Figure 4a).  Because most 
samples were not able to form MCTS from single cells in our polyNIPAAM method, and ascites samples 
are often rich in OCAS, we collected these samples and encapsulated them directly into our 3D PEG-
MAL hydrogel to capture native architecture, cell-cell contacts, and cell type heterogeneity for drug 
screening. These samples were compared to SKOV-3 MCTS, which were formed in polyNIPAAM before 
being transferred to 3D PEG-MAL hydrogels. 
We chose to examine the response to cisplatin and paclitaxel, which are first line clinical 
therapeutics for ovarian cancer, and mafosfamide, a drug that has never been in clinical trials for ovarian 
cancer, but had promising results on TCPS47-48. First, we found that the SKOV-3 MCTS grown in 
polyNIPAAM had similar responses to cisplatin and paclitaxel compared to the patient-derived OCAS 
(Figure 4b). To corroborate that patient-derived OCAS response was the same as what was seen in the 
actual clinical response, we compared our results with pathology reports of the patient samples (Table 
S2). Interestingly, OCAS collected from patients P1, P3 and P6, previously treated with platinum-based 
therapy (cisplatin or carboplatin), predicted cisplatin resistance where TCPS models did not (Figure 4b). 
The exception was high resistance to paclitaxel observed for P6, who had been previously treated with 
this drug, which potentially explains the observed resistance (Table S2). This suggests that OCAS from 
patients transferred directly into 3D PEG-MAL hydrogels may model drug response more accurately than 
TCPS. Surprisingly, mafosfamide, a drug that has never been used to treat ovarian cancer, was more 
effective relative to TCPS against P1 and P3 OCAS (Figure 4b). These data demonstrate that MCTS in 
polyNIPAAM could be a good model for the discovery of new drugs for the treatment of primary ovarian 
cancer. 
 
DISCUSSION  
To the best of our knowledge, a comparative analysis between MCTS formation methods has 
never been reported in a single study. Traditional models generate very large MCTS, generally created 
through the hanging drop method or suspension in non-adherent plates22,25,49. These techniques often 
use just one large MCTS within a well of a 96-well plate, and are limited by the presence of a necrotic 
core50, which affects drug response and assay readout. A system that can generate many smaller MCTS 
(to limit diffusion and hypoxia effects and allow encapsulation in many hydrogels), would be an 
improvement over current 3D drug screening models. The methods described here can generate a large 
number of small MCTS (between 50-150 m) (Figure S8), which were easily recovered and transferred to 
other materials while maintaining high viability (Figure S11). Additionally, these MCTS provided many 
features of tumors, such as oxygen and nutrient diffusion limitations (but not to the extent that a necrotic 
core is present). 
MCTS have previously been used to study tumor biology and drug resistance. However, MCTS 
size, shape and even the ability to form MCTS changes with the method and conditions. Piggott et al. 
formed MDA-MB-231 MCTS with ultra-low adherence plates, while Iglesias et al. failed to do so with the 
same method32-33, likely due to differences in seeding density. Casey et al. found that SKOV-3 cells did 
not form MCTS with the liquid overlay technique51, while in this work we present SKOV-3 MCTS formation 
with all three methods (Figure 1). SkBr3s did not form MCTS when seeded onto soft agar52, but formed 
MCTS in our polyNIPAAM method. Moreover, SkBr3s, MDA-MB-231s, and MDA-MB-468s did not form 
MCTS when seeded in suspension53, but formed large, loose MCTS in our polyNIPAAM method (Figure 
1b). Our polyNIPAAM results are in good agreement with work from the Bissell group using lrECM. For 
example, both works observe a mass phenotype in BT474 and MCF7, a grape-like appearance in AU565, 
SkBr3, and MDA-MB-468.43 These results stress the need to compare the behavior of cell lines across 
multiple MCTS formation methods. 
Our data suggested that cells employ one of two possible mechanisms for MCTS formation: they 
either secrete their own local matrix to provide binding sites and structure, or they rely on cell-cell 
contacts. MCTS formed in the microwells were more likely to increase claudin 4 expression, while those 
formed via confined growth in the polyNIPAAM method or in suspension had higher expression of claudin 
4 and fibronectin (Figure 2a). Immunofluorescence staining has shown that in free MCTS (a MCTS 
configuration with significant spacing between cells) fibronectin is distributed within the intercell space 
throughout the spheroid, while in compact MCTS fibronectin is found on the outer edge of the MCTS54. 
This can be compared with our suspension and polyNIPAAM MCTS, respectively. On the other hand, 
knocking down claudin 4 reduces in vitro MCTS formation55 because it is essential for tight junctions. 
Interesting, claudin 4 is expressed in the majority of ovarian cancers56, and also in our SKOV-3 and 
OVCAR-3 MCTS. Additionally, breast cancer cells grown into MCTS using the overlay method, similar to 
our suspension method, upregulated claudin 4 and several other cell-cell adhesion genes57. These results 
are largely cell-line dependent, without any correlation to cancer type.  
We examined how drug response changed with MCTS formation methods. Changes in drug 
resistance compared to 2D TCPS were greater in MCTS formed in polyNIPAAM or suspension than the 
microwells method (Figure 3b). Decreased sensitivity of cancer MCTS to drug treatment in a 3D model 
versus 2D screening agrees with other studies that have looked at the effect of dimensionality on drug 
response22-27. Both breast cancer cell lines tested were slightly more sensitive to sorafenib in all the three 
methods compared to TCPS, with the exception of AU565 MCTS grown in suspension. This may be 
because sorafenib works as a targeted agent rather than interfering with cell divisions, as 
chemotherapeutic drugs do. We believe that the drug response observed in 3D drug screening is a result 
of the properties of the MCTS culture method. For example, MCTS formed in polyNIPAAM were more 
resistant to first line therapies due to their high proliferation and more compact morphology. 
Finally, we compared our polyNIPAAM MCTS to patient ovarian cancer ascites, because drug 
approval for ovarian cancer therapy has begun to stagnate. Only two ovarian cancer drugs have been 
approved by the U.S Food and Drug Administration (FDA) in the past 10 years58. Therefore, there is a 
pressing need to more accurately model ovarian cancer in vitro to better identify effective treatments. In 
this study, OCAS from patient-derived samples were compared to an established ovarian cancer cell line 
formed in MCTS in polyNIPAAM. In most cases, the patient-derived and cancer cell line MCTS grown in 
polyNIPAAM responded similarly (Figure 4b). Our results suggest that the 3D methods presented here 
may show drug efficacy and drug resistance for an individual patient more accurately than TCPS. 
Interestingly, patient samples were more sensitive to mafosfamide compared to TCPS, a drug that has 
never been in clinical trials for ovarian cancer. This shows that selection of an MCTS method that mimics 
an in vivo environment can facilitate future drug discovery. 
In ovarian cancer, the presence of ascites indicates disease progression and poor prognosis59. 
The disseminated cells and OCAS in the peritoneum are those that become metastatic, and contribute to 
drug resistance and recurrence60-61. Ascites fluid is enriched in cancer stem cells, which can form tumors 
in vivo62. Therefore, patient-specific drug screening of the cells isolated from ascites would be extremely 
beneficial to make treatment decisions that could result in better patient outcomes. The clinical application 
of drug screening to ascites would be relatively easy because the fluid is in great excess in many 
patients. However, only few research groups have performed drug screening in ascites samples50,63, and 
they have demonstrated that ascites responses mimic cell line data. Sensitivity to carboplatin and 
paclitaxel in ascites-derived cells treated in vitro mimicked the clinical chemosensitive or chemoresistant 
phenotype in each patient63. Therefore, MCTS formation methods that can grow MCTS from patient 
derived ascites, can be useful clinical tools. 
Selection of a suitable 3D MCTS model is not straightforward. Drug response in 3D MCTS 
models depends on the cell line and drug of interest, as well as the MCTS formation method. The most 
accurate 3D MCTS model would produce MCTS similar to the in vivo MCTS, as well as exhibit similar 
gene expression. The choice of MCTS formation method may also be based on whether a clonal growth 
method (polyNIPAAM) or an aggregation method (microwells, suspension) is desired. Finally, the time 
requirements of each method are different, which is a practical factor to be considered for drug screening 
assays. 
 
CONCLUSIONS 
We applied three different MCTS formation methods: polyNIPAAM gels, microwells, and 
suspension culture across several cell lines to investigate the implications of these methods on gene 
expression and drug response. To form MCTS with these methods, cells rely on either the production of 
ECM (fibronectin) or the robust expression of cell-cell contact genes (claudin 4). MCTS that were formed 
with the three methods were then used for drug screening in a 3D hydrogel platform. We found that drug 
sensitivity was dependent on MCTS formation technique. To address the need for improved patient 
treatments, we compared the drug response of MCTS of an ovarian cancer cell line grown in polyNIPAAM 
to OCAS obtained directly from patients and we demonstrated that our 3D drug testing platform is a good 
model for patient-derived samples. 
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